trending Market Intelligence /marketintelligence/en/news-insights/trending/_Y4jVJrzT5ykIBq3XUJnnA2 content esgSubNav
In This List

Bayer's lymphoma drug meets primary endpoint in phase 2 trial

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Bayer's lymphoma drug meets primary endpoint in phase 2 trial

Bayer AG's phase 2 trial evaluating the investigational copanlisib treatment for relapsed or refractory indolent non-Hodgkin lymphoma, or iNHL, met its primary endpoint.

Under the study, patients showed an objective response rate of 59.2%, with a complete response rate of 12% and a median duration of response of more than 98 weeks or 687 days, Bayer said in a news release. The full analysis set comprised 142 patients, 141 of which had iNHL.

Non-Hodgkin lymphoma is a type of blood cancer.